Adaptive pathways: can they deliver the triple win?
Adaptive pathways (APs) promise a ‘triple win’. They enable early access for patients to the most promising innovative therapies, address concerns over affordability, cost-effectiveness and outcome uncertainty for payers, whilst meeting companies’ needs to make research and development sustainable.
However, the opportunities and challenges of adaptive pathways are not well understood. This masterclass addresses these strategic issues, illuminating when adaptive pathways are optimal for innovative therapies. Participants will benefit from engaging with the Office of Health Economic’s (OHE) global thought leaders and from insights on how regulatory and reimbursement evidentiary requirements can be aligned to enable timely access to breakthrough therapies.
What will you learn?
- Elements driving uncertainty at an early stage of a treatment introduction, including surrogate endpoints
- Examples on how different types of uncertainty can be addressed, including conditional reimbursement schemes
- What adaptive pathways mean to the development and access to medicines, including impact of early scientific advice
- Examples of early access in Europe
Who may this interest?
- Leaders and managers heading market access, value evidence and health economics and outcome research teams who want to gain insights on the economic arguments in support of early access schemes
- Leaders and managers running medical, government and regulatory affairs teams who want to gain a solid understanding of critical concepts related to market access routes, uncertainty and value assessment
- Researchers and decision-makers who lead initiatives aimed at improving methods and evidence base for value-based, stakeholder-endorsed decision-making
Speakers
Isobel Firth
Senior Economist
Office of Health Economics
Isobel joined OHE in 2020. She has an undergraduate degree in natural sciences, specializing in infectious diseases from the University of Cambridge (UK) and a master’s in public health (MPH) from Imperial College London (UK). Her MPH research focused on inequality in pharmaceutical innovation for infectious diseases and the impact of the World Bank (WA, US) income classification on pharmaceutical innovation. She has completed internships at the World Health Organization and Drugs for Neglected Diseases Initiative (Geneva, Switzerland), where she worked on their Pediatric HIV and Hepatitis C programs. Most recently, she worked at the Wellcome Trust (London, UK) in a number of roles focusing on digital health, innovation and user research. Her research interests include inequality, public health and digital health.
Professor Lotte Steuten
Vice President, Head of Consulting
Office of Health Economics
Lotte’s research interest focuses on the development and application of health economic analysis and health technology assessment (HTA) with the aim of accelerating patient access to high value health care services and treatments. She specializes in quantitative methods for estimating and comparing the expected health and economic benefits of new approaches and interventions in disease prevention, diagnostics and treatment, and prioritizing data collection to efficiently build the evidence for new interventions.
After obtaining her PhD, Lotte has acquired over 10 years of international expertise in leading health economics and HTA projects to inform a wide range of decision problems, working effectively with various academic and non-academic stakeholders including patients, care providers, payers, policy makers, innovators and manufacturers.
Professor Adrian Towse
Director Emeritus and Senior Research Fellow
Office of Health Economics
Professor Adrian Towse is Director Emeritus and Senior Research Fellow of the OHE in the UK. Adrian’s current research includes: incentives for new drugs and vaccines to tackle antimicrobial resistance, the utilization of ‘risk-sharing’ arrangements between health care payers and pharmaceutical companies, including value-based pricing approaches; the economics of pharmacogenetics for healthcare payers and the pharmaceutical industry; economic issues that affect both research and development for and access to treatments for diseases prevalent in the developing world; the economics of medical negligence and measuring productivity in healthcare.
A visiting professor at the London School of Economics and Political Sciences (UK) and a senior researcher at the Nuffield Department of Population Health at the University of Oxford (UK), Adrian has also been a visiting professor at the University of York (UK). For ten years, he served as the Non-Executive Director of the Oxford Radcliffe Hospitals NHS Trust (UK), one of the UK’s largest hospitals. Adrian was President of ISPOR (NJ, US) for the 2014–15 term.
Adrian joined the OHE in 1993 and served as Director there for 25 years. He holds an MA in politics, philosophy and economics from Keble College (the University of Oxford, UK), an MPhil in management studies from Nuffield College (the University of Oxford, UK) and the Oxford Center for Management Studies (UK) and is a member of the Chartered Institute of Management Accountants (London, UK).
In association with
